Cargando…

Corticotrophin-Releasing Factor (CRF) and the Urocortins Are Potent Regulators of the Inflammatory Phenotype of Human and Mouse White Adipocytes and the Differentiation of Mouse 3T3L1 Pre-Adipocytes

Chronic activation of innate immunity takes place in obesity and initiated by the hypertrophic adipocytes which obtain a pro-inflammatory phenotype. The corticotrophin-releasing factor (CRF) family of neuropeptides and their receptors (CRF(1) and CRF(2)) affect stress response and innate immunity. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Dermitzaki, Eirini, Liapakis, George, Androulidaki, Ariadne, Venihaki, Maria, Melissas, John, Tsatsanis, Christos, Margioris, Andrew N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024041/
https://www.ncbi.nlm.nih.gov/pubmed/24835211
http://dx.doi.org/10.1371/journal.pone.0097060
Descripción
Sumario:Chronic activation of innate immunity takes place in obesity and initiated by the hypertrophic adipocytes which obtain a pro-inflammatory phenotype. The corticotrophin-releasing factor (CRF) family of neuropeptides and their receptors (CRF(1) and CRF(2)) affect stress response and innate immunity. Adipose tissue expresses a complete CRF system. The aim of this study was to examine the role of CRF neuropeptides in the immune phenotype of adipocytes assessed by their expression of the toll-like receptor-4 (TLR4), the production of inflammatory cytokines IL-6, TNF-α and IL-1β, chemokines IL-8, monocyte attractant protein-1 (MCP-1) and of the adipokines adiponectin, resistin and leptin. Our data are as follows: (a) CRF, UCN2 and UCN3 are expressed in human white adipocytes as well as CRFR(1a), CRFR(2a) and CRFR(2b) but not CRFR(2c). 3T3L1 pre-adipocytes and differentiated adipocytes expressed both CRF(1) and CRF(2) receptors and UCN3, while UCN2 was detected only in differentiated adipocytes. CRF(2) was up-regulated in mouse mature adipocytes. (b) CRF(1) agonists suppressed media- and LPS-induced pre-adipocyte differentiation while CRF(2) receptor agonists had no effect. (c) In mouse pre-adipocytes, CRF(2) agonists suppressed TLR4 expression and the production of IL-6, CXCL1 and adiponectin while CRF(1) agonists had no effect. (d) In mature mouse adipocytes LPS induced IL-6 and CXCL1 production and suppressed leptin. (e) In human visceral adipocytes LPS induced IL-6, TNF-α, IL-8, MCP-1 and leptin production and suppressed adiponectin and resistin. (f) In mouse mature adipocytes CRF(1) and CRF(2) agonists suppressed basal and LPS-induced production of inflammatory cytokines, TLR4 expression and adiponectin production, while in human visceral adipocytes CRF and UCN1 suppressed basal and LPS-induced IL-6, TNF-α, IL-8 and MCP-1 production. In conclusion, the effects of the activation of CRF(1) and CRF(2) may be significant in ameliorating the pro-inflammatory activity of adipocytes in obesity.